Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus

• Published in: Arthritis care & research (2010) 2012-03, Vol.64 (3), p.375-383
• Main Authors: Mina, Rina, von Scheven, Emily, Ardoin, Stacy P., Eberhard, B. Anne, Punaro, Marilynn, Ilowite, Norman, Hsu, Joyce, Klein‐gitelman, Marisa, Moorthy, L. Nandini, Muscal, Eyal, Radhakrishna, Suhas M., Wagner‐weiner, Linda, Adams, Matthew, Blier, Peter, Buckley, Lenore, Chalom, Elizabeth, Chédeville, Gaëlle, Eichenfield, Andrew, Fish, Natalya, Henrickson, Michael, Hersh, Aimee O., Hollister, Roger, Jones, Olcay, Jung, Lawrence, Levy, Deborah, Lopez‐Benitez, Jorge, McCurdy, Deborah, Miettunen, Paivi M., Quintero‐Del Rio, Ana I., Rothman, Deborah, Rullo, Ornella, Ruth, Natasha, Schanberg, Laura E., Silverman, Earl, Singer, Nora G., Soep, Jennifer, Syed, Reema, Vogler, Larry B., Yalcindag, Ali, Yildirim‐toruner, Cagri, Wallace, Carol A., Brunner, Hermine I.
• Format: Article
• Language: English
• Subjects: Child; Humans; Immunosuppressive Agents - therapeutic use; Lupus Erythematosus, Systemic - drug therapy; Lupus Nephritis - diagnosis; Lupus Nephritis - drug therapy; Male; Remission Induction - methods
• ISSN: 2151-464X; 2151-4658
• DOI: 10.1002/acr.21558

Objective To formulate consensus treatment plans (CTPs) for induction therapy of newly diagnosed proliferative lupus nephritis (LN) in juvenile systemic lupus erythematosus (SLE). Methods A structured consensus formation process was employed by the members of the Childhood Arthritis and Rheumatology Research Alliance after considering the existing medical evidence and current treatment approaches. Results After an initial Delphi survey (response rate = 70%), a 2‐day consensus conference, and 2 followup Delphi surveys (response rates = 63–79%), consensus was achieved for a limited set of CTPs addressing the induction therapy of proliferative LN. These CTPs were developed for prototypical patients defined by eligibility characteristics, and included immunosuppressive therapy with either mycophenolic acid orally twice per day, or intravenous cyclophosphamide once per month at standardized dosages for 6 months. Additionally, the CTPs describe 3 options for standardized use of glucocorticoids, including a primarily oral, a mixed oral/intravenous, and a primarily intravenous regimen. There was consensus on measures of effectiveness and safety of the CTPs. The CTPs were well accepted by the pediatric rheumatology providers treating children with LN, and up to 300 children per year in North America are expected to be candidates for the treatment with the CTPs. Conclusion CTPs for induction therapy of proliferative LN in juvenile SLE based on the available scientific evidence and pediatric rheumatology group experience have been developed. Consistent use of the CTPs may improve the prognosis of proliferative LN, and support the conduct of comparative effectiveness studies aimed at optimizing therapeutic strategies for proliferative LN in juvenile SLE.